Hematological reconstitution and gene therapy: retroviral transfer of the bacterial beta-galactosidase activity into human hematopoietic CD34+ cell populations and into T lymphocytes derived from the peripheral blood

Leukemia. 1995 Oct:9 Suppl 1:S61-3.

Abstract

We report the possibility to transfer marker genes coding for beta-galactosidase activity using retroviral vectors into human peripheral blood CD34+ cells, peripheral blood T-lymphocytes and into the growth factor-dependent human hematopoietic cell line TF-1. Using the MFG-nisLacZ and the FLac vector and various packaging cell lines, we demonstrated retroviral transfer and high expression of a bacterial beta-galactosidase activity induced by the nisLacZ gene or the Sh-ble/LacZ gene. Kinetics of expression of the transgenes were analyzed both in primary cells and cell lines. Absence of cytotoxicity related to the expression of the bacterial beta-galactosidase was assessed in both cell types. These results open interesting prospectives for the use of the beta-galactosidase activity to mark and follow the fate of genetically modified cells isolated from patients prior to reimplantation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD
  • Antigens, CD34
  • Cell Division
  • Cells, Cultured
  • Coculture Techniques
  • Gene Expression
  • Gene Transfer Techniques*
  • Genes, Bacterial
  • Genetic Therapy / methods*
  • Hematopoietic Stem Cells / cytology*
  • Hematopoietic Stem Cells / immunology
  • Hematopoietic Stem Cells / pathology
  • Humans
  • Neoplasms / blood
  • Neoplasms / immunology
  • Retroviridae*
  • T-Lymphocytes* / immunology
  • T-Lymphocytes* / pathology
  • beta-Galactosidase / biosynthesis
  • beta-Galactosidase / genetics*

Substances

  • Antigens, CD
  • Antigens, CD34
  • beta-Galactosidase